IBAM completes US$690m deal

Through the transaction, announced in August 2016 and now approved by the regulatory authorities, IBA Molecular creates a portfolio of diagnostic solutions for over 14 million patients. Nuclear imaging will continue to be at the core of the enlarged organisation as the business plans to invest further in organic and inorganic growth opportunities.

IBA Molecular will roll out a new brand to reflect the combined strengths in PET und SPECT imaging.  In the meantime, the two businesses will continue to engage with customers and suppliers as IBA Molecular and Mallinckrodt Nuclear Imaging, and it will be business as usual for customers and suppliers. 

Renaud Dehareng, current CEO of IBA Molecular and the new CEO of the enlarged Group, said: “We have created a world-class provider in nuclear imaging. The figures speak for themselves. We will use our scale, global reach, manufacturing footprint and experience to deliver a superior and more sharply focused service that our customers can rely upon everyday.”

Commenting on behalf of CapVest, the owner of the enlarged business, Kate Briant, CapVest Partner and Chairman of the Board, said: “Nuclear imaging is an essential diagnostic tool in modern medicine, underpinned by positive long-term fundamentals. We are thrilled to have completed this acquisition as it further consolidates the Group’s leadership position in this attractive segment. We believe there will be lots of future growth opportunities to exploit as we seek to grow the market in the coming years. We look forward to working closely with Renaud and his new leadership team as they pursue their ambitious growth plans for the business.”